Deception’s justifiability might depend on clinicians’ commitment to solidarity and awareness of social determinants of patients’ vulnerability to HIV infection.
AMA J Ethics. 2021;23(5):E382-387. doi:
10.1001/amajethics.2021.382.
Rayner Kay Jin Tan, Jane Mingjie Lim, MSW, and Jeremiah Kah Wai Chan, MSc
Merits and drawbacks of U = U messaging are ethically and clinically complex, and drawbacks could harm patients in whom viral suppression is hard to achieve.
AMA J Ethics. 2021;23(5):E418-422. doi:
10.1001/amajethics.2021.418.
Camillo Lamanna, MMathPhil, MBBS and Lauren Byrne, MBBS
Perhaps machine learning systems trained on patients’ electronic health records and social media footprints could be used as decision aids when patients lack capacity or face overwhelming decisions.
AMA J Ethics. 2018;20(9):E902-910. doi:
10.1001/amajethics.2018.902.
Divya Yerramilli, MD, MBE, Alexandra Charrow, MD, MBE, and Arthur Caplan, PhD
Physicians should be aware of the powerful impact celebrities’ cancer narratives can have on patients’ experiences of their illnesses and treatment decisions. Partnering with celebrities is one strategy for delivering evidence-based health information and messaging to the public.
AMA J Ethics. 2018;20(11):E1075-1081. doi:
10.1001/amajethics.2018.1075.
Trafficking-specific ICD-10-CM codes account for physical, social, and psychological dimensions of trafficked patients’ experiences. Data collected by clinicians can also motivate improvements in health policy, resource allocation, and prevention.
AMA J Ethics. 2018;20(12):E1143-1151. doi:
10.1001/amajethics.2018.1143.
Marissa Chaet Brykman, JD, Virginia Streusand Goldman, PhD, Nandakumara Sarma, PhD, RPh, Hellen A. Oketch-Rabah, PhD, MSc, Deborah Biswas, JD, and Gabriel I. Giancaspro, PhD
Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.
AMA J Ethics. 2022;24(5):E382-389. doi:
10.1001/amajethics.2022.382.
Dr Amy B. Cadwallader, Joshua J. Klein, and Scott J. Schweikart join this episode of Ethics Talk to discuss safety and limited legal means of reining in social media influencers' advertisements about dietary supplements.